Refine
Year of publication
- 2016 (57) (remove)
Document Type
- Book chapter (57) (remove)
Is part of the Bibliography
- yes (57)
Institute
- Informatik (23)
- ESB Business School (15)
- Technik (11)
- Life Sciences (6)
- Texoversum (1)
Publisher
- Springer (29)
- Gesellschaft für Informatik e.V (11)
- Wiley (6)
- Elsevier (3)
- Routledge (3)
- De Gruyter (1)
- Economica (1)
- Nova Science Publishers (1)
- Public Verlagsgesellschaft und Anzeigenagentur (1)
- Vahlen (1)
For many companies, it is major international sporting events (in particular the Football World Cup or the Olympic Games) that constitute the ideal platform for the integration of their target group-specific marketing communication into an attractive sports environment. Sports event organizers sell exclusive marketing rights for their events to official sponsors, who, in return, acquire exclusive options to utilize the event for their own advertising purposes. Ambush marketing is the method used by companies that do not hold marketin rights to an event, but still use their marketing activities in diverse ways to establish a connection to it. There is still whidespread debate and confusion about the topic. Ambush marketing is often defined in different ways, by different people, according to their position as either supporters of opponents of the practice.
As long as there have been professional sports, there have been relationships on different levels. For example, sponsorship (or patronage as it was called in the early days) was mostly based on personal relations between the local benefactors and their favourite sports club. Regarding media, clubs always maintained special relationships with selected journalists. The bond between fans and their clubs was always a close and mutually beneficial one. All these relationships existed from the start of the sports business. Therefore, relationship marketing is nothing new in the context of sports. Many sporting organisations always knew to value a deep and good relationship with their stakeholders and practised relationship marketing without being aware of it. Successful sports managers, however, take the old wisdom and turn it into a modern relationship marketing approach by structuring the various relationships in order to make them more effective and profitable for the own sporting organisation and the various stakeholders. This chapter ... illustrates the many facets of relationship marketing and the possibilities it offers in the context of the sports business.
It is known that the costs related with drug research and development (R&D) and the timelines to develop a new drug increased over the past years. In parallel, the success rates of drug projects along the pharmaceutical R&D phases are still very low, and the outcome of all R&D efforts is stagnating. In consequence, the R&D efficiency defined as the financial investment per drug has been steadily decreasing. As innovation is the major growth driver of the pharmaceutical industry, reliable data on R&D efficiency and new concepts to overcome these challenges are of great interest for R&D managers and the sustainability of the pharmaceutical industry as a whole. This book chapter reviews publications on R&D performance indicators of the past years, such as the success rates and timelines per phase. Additionally, it illustrates the factors influencing the success rates, timelines, and costs of pharmaceutical R&D most and, thus, the denominators of the R&D efficiency.
Clinical development is historically the phase in which a potential new medicine is being tested in phase 2 and phase 3 patient trials to demonstrate the new molecules' efficacy and safety to support the regulatory approval of drugs by health authorities. This relatively focused approach has been considerably expanded by a number of forces from within the pharmaceutical industry and equally important by changes in the healthcare systems. The need to identify the optimal patient population, showstoppers leading to discontinuation of clinical programs, the silent but constant removal of surrogate endpoints for registration, and the increased demand for real-life data which are used to demonstrate the patients' benefit and which have an ever-increasing role for pricing and reimbursement negotiations are today an integral part of this phase.
This chapter will review both the nuts and bolts of clinical development but also recent developments in this area which shape the environment and how the different players have reacted and what options might need to be explored in the future.
The reduced research and development (R&D) efficiency, strong competition from generics, increased cost pressure from payers, and an increased biological complexity of new target indications have resulted in a rethinking and a change from a traditional and more closed R&D model in the pharmaceutical industry toward the new paradigm of open innovation. In the past years, pharmaceutical companies have broadened their external networks toward research collaborations with academic institutes, technology providers, or codevelopment partners. To fulfill the demand to reduce timelines and costs, research-based pharmaceutical companies started to outsource R&D activities. In addition, internal R&D processes were adjusted to the more open R&D model and new processes such as alliance management were established. The corporate frontier of pharmaceutical companies became permeable and more open. As a result, the focus of pharmaceutical R&D expanded from a purely internal toward a mixed internal and external model. Today, the U.S. pharmaceutical company Eli Lilly may have established the most open model toward external innovation, as it has integrated its innovation processes with its business model. Other companies are following this more open R&D model with newer concepts such as new frontier sciences, drug discovery alliances, private public partnerships, innovation incubators, virtual R&D, crowdsourcing, open source innovation, and innovation camps.
The efficiency of pharmaceutical research and development (R&D) reflected by increasing costs of R&D, long timelines, and low probabilities of technical and regulatory success decreased continuously in the past years. Today, the costs for discovering and developing a new drug are enormously high with more than USD 2 billion per new molecular entity (NME), while the average overall success of a research project to provide an NME is in the single-digit percentage rate, and the total timelines of R&D easily exceeds 10 years questioning the return on investment (ROI) of pharmaceutical R&D. As a consequence and also caused by numerous patent expirations of blockbuster drugs that increased the pressure to return to an acceptable ROI, the pharmaceutical industry addressed this challenge and the related causes and identified several actions that need to be taken to increase the output/input ratio of R&D. This book chapter will review the pipeline sizes and the R&D investments of multinational pharmaceutical companies, will describe new processes that have been implemented to increase the reach and to reduce costs of pharmaceutical R&D, and it will illustrate new innovation models that were developed to increase the R&D efficiency.
Die Analyse der geometrischen Parameter der Werkzeuge und der kinematisch bedingten Eingriffsverhältnisse beim Fräsen führen zu einer erheblichen Beeinflussung der Schneidenbelastungen während des Einsatzes. Eine exzentrische Aufnahme von Schaftwerkzeugen bedeutet eine deutliche Belastung der exzentrischen Schneiden. Diese Belastung liegt deutlich über der durch die Ungleichteilung erzeugten Kraftmodulation. Weiterhin werden durch die Impulsbelastung der Schneideneintritte die Resonanzen der Struktur angeregt. Dies beeinflusst zum einen die Messungen mit der Kraftmessplattform. Zum anderen werden während der realen Bearbeitung durch diese Wechselwirkung die Oberflächen der bearbeiteten Bauteile beeinflusst.
Das Ziel der vorliegenden Studie war es, den Zusammenhang zwischen der Implementierung von CRM-Prozessen und der Kundenzufriedenheit zu analysieren. Unsere Untersuchung ist einigen grundsätzlichen Beschränkunfen unterworfen. CRM ist immer noch ein relativ junges Forschungsgebiet, dessen Prozesse sich im Zeitablauf mit großer Wahrscheinlichkeit noch weiterentwickeln werden. Manche Praktiken werden als ineffektiv identifiziert und verworfen werden; andere existierende Prozesse werden eine Verbesserung erfahren. Es ist zudem zu erwarten, dass neue Prozesse und Aktivitäten entwickelt und eingeführt werden. Als Folge dieser Entwicklungen ist es möglich, dass die hier berichtete Wirkung auf die Kundenzufriedenheit durch die Implementierung von CRM-Prozessen sich im Laufe der Zeit ebenfalls ändern wird. Ein interessanter Forschungsansatz wäre daher die Beobachtung dieser Evolution im Zeitablauf.
Darüber hinaus muss in dieser Studie beachtet werden, dass die Kundenzufriedenzeit lediglich ein vorökonomisches Ziel des CRM ist. Einzelne Investitionen in eine bestehende Geschäftsbeziehung müssen anhand der Wertigkeit des Kunden für das Unvernehmen vorgenommen werden.Bestehen ferner keine Alternativen zum bisherigen Anbieter, so ist es ökonomisch nicht sinnvoll, Ressourcen zur Steigerung der Kundenzufriedenheit einzusetzen, da ein Wechsel des Anbieters unwahrscheinlich ist.
Schließlich nutzten wir für die vorliegende Studie Skalen zur Einschätzung der Einstellungen der Kunden durch die Unternehmen. Da dieses Vorgehen möglichst genaue Beurteilungen erfordert, kann es sein, dass die Daten gewisse Verzerrungen aufweisen. Zukünftige Forschungsansätze könnten die Studie durch eine ergänzende Einschätzung der Kunden zur Kreuzvalidierung sinnvoll erweitern.
The evolution of Services Oriented Architectures (SOA) presents many challenges due to their complex, dynamic and heterogeneous nature. We describe how SOA design principles can facilitate SOA evolvability and examine several approaches to support SOA evolution. SOA evolution approaches can be classified based on the level of granularity they address, namely, service code level, service interaction level and model level. We also discuss emerging trends, such as microservices and knowledge-based support, which can enhance the evolution of future SOA systems.